UBS Bullish on Merck (MRK) Following Verona Pharma Purchase

Merck & Co., Inc. (NYSE:MRK) ranks among the best magic formula stocks to invest in. On July 10, UBS reiterated its Buy rating and $105 price target for Merck & Co., Inc. (NYSE:MRK). Analyst Trung Huynh remained optimistic about the pharmaceutical giant after Merck confirmed that it would acquire London-based Verona Pharma for $10 billion.

UBS Bullish on Merck (MRK) Following Verona Pharma Purchase

Pixabay/Public Domain

According to consensus estimates of $3.7 billion, the acquisition represents about 2.7 times peak sales, which is consistent with industry norms, according to UBS. The firm believes that Ohtuvayre’s launch should benefit from Merck’s size and business acumen, much like recent deals like Acceleron.

In a call, Merck & Co., Inc. (NYSE:MRK) stated it remains open to $1 billion to $15 billion in additional acquisitions, which UBS believes will be needed to counteract the 2028 Keytruda patent cliff.

Merck & Co., Inc. (NYSE:MRK) is a well-known American multinational pharmaceutical firm. Internationally recognized as Merck Sharp & Dohme (MSD), the company is a global provider of prescription medications, vaccines, biologic therapies, and animal health products.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.